| CEE countries | All other countries (including UK/Ireland) | ||||
| Denominator | 390 | 15 101 | |||
| % (95% CI) (n) | % (95% CI) (n) | p Value* | Age-adjusted OR† (95% CI) | p Value* | |
| 1+ Acute STI | 29.0% (24.5% to 33.8%) (113) | 27.2% (26.5% to 27.9%) (4108) | 0.438 | 1.07 (0.85 to 1.33) | 0.578 |
| HIV | 0.8% (0.2% to 2.2%) (3) | 0.8% (0.7% to 1.0%) (121) | 0.944 | 1.09 (0.34 to 3.45) | 0.885 |
| Gonorrhoea | 5.6% (3.6% to 8.4%) (22) | 3.9% (3.6% to 4.2%) (590) | 0.083 | 1.47 (0.95 to 2.28) | 0.086 |
| Chlamydia | 6.7% (4.4% to 9.6%) (26) | 6.6% (6.2% to 7.0%) (1002) | 0.980 | 0.94 (0.63 to 1.41) | 0.759 |
| Syphilis | 1.0% (0.3% to 2.6%) (4) | 0.4% (0.3% to 0.5%)(64) | 0.076 | 2.98 (1.07 to 8.29) | 0.037 |
| HSV (first attack) | 0.8% (0.2% to 2.2%) (3) | 1.5% (1.3% to 1.7%) (229) | 0.230 | 0.53 (0.17 to 1.68) | 0.283 |
| Genital warts (first attack) | 4.1% (2.4% to 6.6%) (16) | 4.5% (4.1% to 4.8%) (672) | 0.742 | 0.88 (0.53 to 1.45) | 0.606 |
| Trichomonas | 0.3% (<0.01% to 1.4%) (1) | 0.1% (<0.01% to 0.2%) (13) | 0.269 | 3.66 (0.47 to 28.6) | 0.216 |
| NG/NSU | 13.1% (9.9% to 16.8%) (51) | 12.5% (12.0% to 13.0%) (1885) | 0.726 | 1.05 (0.78 to 1.41) | 0.771 |
| NG/NSI | 1.5% (0.6% to 3.3%) (6) | 0.7% (0.5% to 0.8%) (101) | 0.041 | 2.43 (1.06 to 5.60) | 0.036 |
*p Value for comparison between visits made by patients from central and eastern European (CEE) countries and patients from all other countries.
†Age-adjusted odds ratio (OR) for patients from CEE countries relative to patients from all other countries.
GUM, genitourinary medicine; HSV, herpes simplex virus; NG/NSI, complicated non-gonococcal/non-chlamydial infection; NG/NSU, non-gonococcal/non-specific urethritis; STI, sexually transmitted infection.